SEARCH

SEARCH BY CITATION

References

  • Addiego, Jr, J.R., Kasper, C., Abildgaard, C., Lusher, M., Hilgertner, M., Glader, B., Aledort, L., Hurst, D. & Bray, G. (1994) Increased frequency of inhibitors in African American hemophilia A patients [Abstract]. Blood, 84(Suppl. 1), 239a.
  • Antovic, J., Schulman, S., Eelde, A. & Blomback, M. (2001) Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with hemophilia A. Haemophilia, 7, 557560.
  • Astermark, J., Berntorp, E., White, G.C. & Kroner, B.I., MIBS Study Group. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia, 7, 267272.
  • Astermark, J., Oldenburg, J., Pavlova, A., Berntorp, E. & Lefvert, A.K. (2006a) Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with hemophilia A. Blood, 107, 31673172.
  • Astermark, J., Oldenburg, J., Carlson, J., Pavlova, A., Kavakli, K., Berntorp, E. & Lefvert, A.K., for the MIBS Study Group. (2006b) Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood, 108, 37393745.
  • Astermark, J., Donfield, S.M., DiMichele, D.M., Gringeri, A., Gilbert, S.A., Waters, J. & Berntop, E., for the FENOC Study Group. (2007a) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative Study. Blood, 109, 546551.
  • Astermark, J., Rocino, A., Von Depka, M., Van Den Berg, H.M., Gringeri, A., Mantovani, L.G., Morado, M., Garrido, R.P., Schiavoni, M., Villar, A., Windyga, J. & The EHTSB. (2007b) Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia, 13, 3845.
  • Barrowcliffe, T.W. (2005) Standardization of assays. In: Textbook of Hemophilia. (ed. byC.Lee, E.Berntorp & K.W.Hoots ), pp. 242248. Blackwell Publishers, Oxford.
  • Batorova, A. & Martinowitz, U. (2006) Continuous infusion of coagulation factors: current opinion. Current Opinions in Hematology, 13, 308315.
  • Bech, R.M. (1996) Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis, 26, 135138.
  • Belvini, D., Salviato, R., Radossi, P., Pierobon, F., Mori, P., Castaldo, G. & Tagariello, G. AICE HB Study Group. (2005) Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica, 90, 635642.
  • Berntorp, E., Shapiro, A., Astermark, J., Blanchette, V.S., Collins, P.W., DiMichele, D., Escuriola, C., Hay, C.R., Hoots, W.K., Leissinger, C.A., Negrier, C., Oldenburg, J., Peerlinck, K., Reding, M.T. & Hart, C. (2006) Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia, 12(Suppl. 6), 17.
  • Brackmann, H.H. (1984) Induced immunotolerance in factor VIII inhibitor patients. Progress in Clinical and Biological Research, 150, 181195.
  • Brackmann, H.H., Oldenburg, J. & Schwaab, R. (1996) Immune tolerance for the treatment of FVIII inhibitors-twenty years of the Bonn protocol. Vox Sanguinis, 70(Suppl.), 3035.
  • Briet, E. (1991) Factor IX inhibitor in hemophilia B patients: their incidence and prospects for development with high purity factor IX products. Blood Coagulation & Fibrinolysis, 2, 4750.
  • Brown, S.A. (2005) Treatment of inhibitors in hemophilia B. In: Textbook of Hemophilia. (ed. by C.Lee, E.Berntorp & K.W.Hoots ), pp. 101105. Blackwell Publishers, Oxford.
  • Carcao, M.D., Connolly, B.L., Chait, P., Stain, A.M., Acebes, M., Massicotte, P. & Blanchette, V.S. (2003) Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia, 9, 578583.
  • Carmassi, F., Giannarelli, C., DeGiorgi, A. & DeNegri, F. (2007) Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs. Haemophilia, 13, 106107.
  • Christophe, O.D., Lenting, P.J., Cherel, G., Boon-Spijker, M., Lavergne, J.M., Boertjes, R., Briquel, M.E., De Goede-Bolder, A., Goudemand, J., Gaillard, S., D'Oiron, R., Meyer, D. & Mertens, K. (2001) Functional mapping of anti-factor IX inhibitors developed in patients with severe haemophilia B. Blood, 98, 14161423.
  • Cross, D.C. & Van Den Berg, H.M. (2007) Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia, 13, 111114.
  • DiMichele, D. (2005) Inhibitors to factor VIII – epidemiology and treatment. In: Textbook of Hemophilia. (ed. byC.Lee, K.Hoots & E.Berntorp ), pp. 6470. Blackwell Science, Oxford.
  • DiMichele, D.M. & Kroner, B. and the North American Immune Tolerance Study Group. (2002) The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Journal of Thrombosis and Haemostasis, 87, 5257.
  • Dobryznski, E. & Herzog, R.W. (2005) Tolerance induction by viral in vivo gene transfer. Clinical Medicine & Research, 3, 234240.
  • Ehrlich, H.J., Henzl, M.J. & Gomperts, E.D. (2002) Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia, 8, 8390.
  • Ewenstein, B.M., Takemoto, C., Warrier, I., Lusher, J., Saidi, P., Eisele, J., Ettinger, L.J. & DiMichele, D. (1997) Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood, 89, 11151116.
  • Fox, R.A., Neufeld, E.J. & Bennett, C.M. (2006) Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia, 12, 218222.
  • Freiburghaus, C., Berntorp, E., Ekman, M., Gunnarsson, M., Kjellberg, B. & Nilsson, I.M. (1999) Tolerance induction using the Malmo treatment model 1982–1995. Haemophilia, 5, 3239.
  • Giles, A.R., Verbruggen, B., Rivard, G.E., Teitel, J. & Walker, I. (1998) A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thrombosis and Haemostasis, 79, 872875.
  • Gill, F.M. (1984) The natural history of factor VIII inhibitors in patients with hemophilia A. Progress in Clinical and Biological Research, 150, 1929.
  • Goudemand, J., Rothschild, C., Demiguel, V., Vinciguerrat, C., Lambert, T., Chambost, H., Borel-Derlon, A., Claeyssens, S., Laurian, Y. & Calvez, T., FVIII-LFB and Recombinant FVIII study groups. (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood, 107, 4651.
  • Gouw, S.C. Van Der Bom, J.G. & Van Den Berg, H.M. (2007a) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 109, 46484654.
  • Gouw, S.C., Van Der Bom, J.G., Auerswald, G., Ettinghausen, C.E., Tedgard, U. & Van Den Berg, H.M. (2007b) Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood, 109, 46934697.
  • Green, P. (2004) A Database of Point Mutations and Short Additions and Deletions in the Factor IX Gene. Haemophilia B Mutation Database, King's College London, University of London, London, Version 13. http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html (accessed April 2, 2007)
  • Greenwood, R., Wang, B., Midkiff, K., White, G.C., Lin, H.F. & Frelinger, J.A. (2003) Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice. Journal of Thrombosis and Haemostasis, 1, 95102.
  • Harper, J.L., Gill, J.C., Hopp, R.J., Evans, J. & Haire, W.D. (1995) Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor. Thrombosis and Haemostasis, 74, 10391041.
  • Hay, C.R., Baglin, T.P., Collins, P.W., Hill, F.G. & Keeling, D.M. (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). British Journal of Haematology, 111, 7890.
  • Hay, C.R.M., Brown, S., Collins, P.W., Keeling, D.M. & Liesner, R. (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors’ Organization. British Journal of Haematology, 133, 591605.
  • High, K.A. (1995) Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. Advances in Experimental Medicine and Biology 386, 7986.
  • Hilgartner, M.W., Makipernaa, A. & DiMichele, D.M. (2003) Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia, 9, 261268.
  • Hoffman, M. & Monroe, III, D.M. (2001) The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology, 38(Suppl. 12). 69.
  • Ingerslev, J. (2005) Laboratory assays in haemophilia. In: Textbook of Hemophilia. (ed. byC.Lee, E.Berntorp & K.W.Hoots ), pp. 235241. Blackwell Publishers, Oxford.
  • Ingerslev, J., Freidman, D., Gastineau, D., Gilchrist, G., Johnsson, H., Lucas, G., McPherson, J., Preston, E., Scheibel, E. & Shuman, M. (1996) Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis, 26(Suppl. 1), 118123.
  • Jansen, M., Schmaldienst, S., Banyai, S., Quehenberger, P., Pabinger, I., Derfler, K., Horl, W.H. & Knobl, P. (2001) Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). British Journal of Haematology, 112, 9197.
  • Kadar, J.G., Schuster, J. & Hunzelmann, N. (2007) IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A. Haemophilia, 13, 104105.
  • Kasper, C. (1975) Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica, 33, 640644.
  • Katz, J. (1996) Prevalence of FIX Inhibitors among patients with hemophilia B: results of large scale North America survey. Haemophilia, 2, 2831.
  • Kavalki, K., Makris, M., Zulfikar, B., Erhardtsen, E., Abrams, Z.S. & Kenet, G. (2006) Home treatment of harmarthorses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomized, double-blind, cross-over trial. Thrombosis and Haemostasis, 95, 600605.
  • Kenet, G., Lubetsky, A., Luboshitz, J. & Martinowitz, U. (2003) A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). Journal of Thrombosis and Haemostasis, 1, 450455.
  • Ketterling, R.P., Vielhaber, E.L., Lind, T.J., Thorland, E.C. & Sommer, S.S. (1994) The rates and patterns of deletions in the human factor IX gene. American Journal of Human Genetics, 54, 201213.
  • Key, N.S. (2004) Inhibitors in congenital coagulation disorders. British Journal of Haematology, 127, 379391.
  • Key, N.S., Aledort, L.M., Beardsley, D., Cooper, H.A., Davignon, G., Ewenstein, B.M., Gilchrist, G.S., Gill, J.C., Glader, B., Hoots, W.K., Kisker, C.T., Lusher, J.M., Rosenfield, C.G., Shapiro, A.D., Smith, H. & Taft, E. (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in hemophiliacs with inhibitors. Journal of Thrombosis and Haemostasis, 80, 912918.
  • Konkle, B.A., Ebbesen, L.S. & Friedrich, U.. (2006) Secondary prophylactic treatment with rFVIIa in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment: analysis of primary endpoint and safety. Poster presented at: XXVII International Congress of the World Federation of HemophiliaMay 21–25; 2006; Vancouver, Canada. Haemophilia, 12(Suppl. 2), 66.
  • Kreuz, W., Escuriola-Ettingshausen, C., Mentzer, D., Martinez, I., Becker, S., Stoll, H. & Heller, C. (2000) Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors [Abstract]. Blood, 96, 266a.
  • Largo, R., Sigg, P., Von Felten, A. & Straub, P.W. (1974) Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. British Journal of Haematology, 26, 129140.
  • Leissinger, C.A. (2006) Prophylaxis in haemophilia patients with inhibitors. Haemophilia, 12(Suppl. 6), 6773.
  • Lin, H.F., Maeda, N., Smithies, O., Straight, D.L. & Stafford, D.W. (1997) A coagulation factor IX-deficient mouse model for human hemophilia B. Blood, 90, 39623966.
  • Lisman, T., Mosnier, L.O., Lambert, T., Mauser-Bunschoten, E.P., Meijers, J.C., Nieuwenhuis, H.K. & De Groot, P.G. (2002) Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood, 99, 175179.
  • Ljung, R.C. (1995) Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematologica, 94, 4952.
  • Ljung, R., Petrini, P., Tengborn, I. & Sjorin, E. (2001) Haemophilia B mutations in Sweden: a population based study of mutational heterogeneity. British Journal of Haematology, 113, 8186.
  • Lollar, P. (2005) Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. Journal of Thrombosis and Haemostasis, 2, 10821095.
  • Lorenzo, J.I., Lopez, A., Altisent, C. & Aznar, J.A. (2001) Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. British Journal of Haematology, 3, 600603.
  • Lozier, J.N., Tayebi, N. & Zhang, P. (2005) Mapping of genes that control the antibody response to human factor IX in mice. Hemostasis, Thrombosis, and Vascular Biology, 105, 10291035.
  • Ludlam, C.A. (2002) The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiology of Haemostasis and Thrombosis, 32(Suppl. 1), 1318.
  • Lusher, J.M., Blatt, P.M., Penner, J.A., Aledort, L.M., Levine, P.H., White, G.C., Warrier, A.I. & Whitehurst, D.A. (1983) Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood, 62, 11351138.
  • Lusher, J.M., Roberts, H.R., Davignon, G., Joist, J.H., Smith, H., Shapiro, A., Laurian, Y., Kasper, C.K. & Mannucci, P.M. (1998) A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous hemorrhages in persons with hemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia, 4, 790798.
  • Manco-Johnson, M.J., Abshire, T.C., Brown, D., Buchanan, G.R., Cohen, A.R., DiMichele, D., Hoots, W.K., Leissinger, C.A., McRedmond, K., Nugent, D.J., Shapiro, A.D., Thomas, G.A., Valentino, L.A. & Riske, B. (2005) Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency [Abstract]. Blood, 106, 3.
  • Mariani, G. & Kroner, B. (2001) Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica, 86, 11861193.
  • Mathias, M., Khair, K., Hann, I. & Liesner, R. (2004) Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia. British Journal of Haematology, 125, 366368.
  • Matsumoto, T., Shima, M., Takeyama, M., Yoshida, K., Tanaka, I., Sakurai, Y., Giles, A.R. & Yoshioka, A. (2006) The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. Journal of Thrombosis and Haemostasis, 4, 377384.
  • Mehta, R., Parameswaran, R. & Shapiro, A.D. (2006) An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia, 12(Suppl. 6), 5461.
  • Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A. & Herzog, R.W. (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. Journal of Clinical Investigation, 111, 13471356.
  • Morfini, M., Lee, M. & Messori, A. (1991) The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Hemostasis. Thrombosis and Haemostasis, 66, 384386.
  • Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C. & Lauroua, P. (1997) Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Journal of Thrombosis and Haemostasis, 77, 11131119.
  • Negrier, C., Dargaud, Y., Bordet, J.C. (2006) Basic aspects of bypassing agents. Haemophilia, 12(Suppl. 6), 4853.
  • Nilsson, I.M., Berntorp, E. & Zetterval, O., (1986) Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proceedings of the National Academy of Sciences of the United States of America, 83, 91699173.
  • Oldenburg, J. & Pavlova, A. (2006) Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia, 12(Suppl. 6), 1523.
  • Pipe, S.W. (2005) The promise and challenges of bioengineered recombinant clotting factors. Journal of Thrombosis and Haemostasis, 3, 16921701.
  • Santagostino, E., Mancuso, M.E., Rocino, A., Mancuso, G., Scaraggi, F. & Mannucci, P.M. (2006) A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. Journal of Thrombosis and Haemostasis, 4, 367371.
  • Sawamoto, Y., Shima, M., Yamamoto, M., Kamisue, S., Nakai, H., Tanaka, I., Hayashi, K., Giddings, J.C. & Yoshioka, A. (1996) Measurement of anti-factor IX IGG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thrombosis Research, 83, 279286.
  • Schulman, S., D'Oiron, R., Martinowitz, U., Pasi, J., Briquel, M.E., Mauser-Bunschoten, E., Morfini, M., Ritchie, B., Goudemand, J., Lloyd, J., McPherson, J., Negrier, C., Peerlinck, K., Petrini, P. & Tusell, J. (1998) Experiences with continuous infusion of recombinant activated factor VII. Blood Coagulation & Fibrinolysis, 9(Suppl. 1), S97S101.
  • Shapiro, A.D., Gilchrist, G.S., Hoots, W.K., Cooper, H.A. & Gastineau, D.A. (1998) Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery. Journal of Thrombosis and Haemostasis, 80, 773778.
  • Thorland, E.C., Dost, J.B., Lusher, J.M., Warrier, I., Shapiro, A., Koerper, M.A., Dimichele, D., Westman, J., Key, N.S. & Sommer, S.S. (1999) Anaphylactic response to FIX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia, 5, 101105.
  • Turecek, P.L., Varadi, K., Gritsch, H., Schwarz, H.P. (2004) FEIBA: mode of action. Haemophilia, 10(Suppl. 2), 39.
  • UK Haemophilia Centre Doctors’ Organisation (UKHCDO). (2004) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. Journal of Thrombosis and Haemostasis, 2, 10471054.
  • Van der Bom, J.G., Mauser-Bunschoten, E.P., Fischer, K. & Van Den Berg, H.M. (2003) Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Journal of Thrombosis and Hemostasis, 3, 475479.
  • Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., Van Den Berg, H.M. & Mauser-Bunschoten, E. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitor. Improved specificity and reliability. Thrombosis and Haemostasis, 73, 247251.
  • Von Auer, C., Oldenburg, J., Auerswald, G., Von Depka-Prodzinski, M., Eifrig, B., Escuriola-Ettinghausen, C., Heinrichs, C., Klamroth, R., Kreuz, W., Kurnik, K., Lenk, H., Pollmann, H., Siegmund, B., Syrbe, G., Varvenne, M., Wolf, H.H., Zimmermann, R. & Scharrer, I. (2003) The development of inhibitors directed against factor VIII after continuous infusion factor VIII concentrate on patients with hemophilia A. Journal of Thrombosis and Haemostasis, 1(Suppl. 1), 1623.
  • Warrier, I. (2005) Inhibitors in haemophilia B. In: Textbook of Hemophilia. (ed. byC.Lee, E.Berntorp & K.W.Hoots ), pp. 97100. Blackwell Publishers, Oxford.
  • Warrier, I., Ewenstein, B., Koerper, M., Shapiro, A., Key, N., DiMichele, D., Miller, R., Pasi, J., Rivard, G., Sommer, S., Katz, J., Bergmann, F., Ljung, R., Petrini, P. & Lusher, J. (1997) FIX inhibitors and anaphylaxis in hemophilia B. Journal of Pediatric Haematology and Oncology, 19, 2327.
  • Wermes, C., Von Depka Prondzinski, M., Welte, K. & Sykora, K.-W. (2000) New strategy for the treatment of factor IX inhibitors in severe haemophilia B. Blood, 96, 267a.
  • Young, G., Blain, R., Nakagawa, P. & Nugent, D.J. (2006) Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia, 12, 598604.